The diagnostic and therapeutic challenges of Grade 3B follicular lymphoma

Grade 3B follicular lymphoma (G3B FL) is rare, accounting for only 5-10% of FLs. Not only has it been routinely excluded from clinical trials, but data published on diagnosis, outcomes, choice of therapies and role of imaging are conflicting. With the advent of increasingly diverse treatment options for low-grade (G1-3A) FL, and the molecular subcategorisation of high-grade B-cell lymphomas, characterisation and treatment of G3B FL is ever more important as extrapolation of data becomes more difficult. New data have emerged exploring unique genetic characteristics, specific features on positron emission tomography imaging, choice of therapy, and outcomes of G3B FL in the current era. The present review will summarise and appraise these new data, and offer recommendations based on current evidence.

Automated summary

Grade 3B follicular lymphoma is rare and often excluded from clinical trials, leading to conflicting data on diagnosis, outcomes, therapy choices, and imaging role. New research is exploring unique genetic characteristics, PET imaging features, therapy choices, and outcomes in the current era, highlighting the importance of characterization and treatment of G3B FL.